Endonovo Therape Financials

ENDV

Source SEC Filings (10-K/10-Q) Data as of Sep 30, 2023 Currency USD FYE December

This page shows Endonovo Therape (ENDV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ENDV FY2022 2026-04-22

High reported gross margin does not offset tiny revenue scale, leaving Endonovo reliant on external funding to keep operating.

From FY2021 to FY2022, cash nearly disappeared from $85.9K to $0 while financing inflows of $593.0K still failed to cover -$678.8K of operating cash burn; that helps explain why shares outstanding jumped from 72.0M to 194.3M even though revenue was only $135.4K. The business is being funded more by recapitalization than by customers.

Gross margin stayed high at 92.6% in FY2022, but that produced only $125.4K of gross profit against an operating loss of -$3.3M. Similar margins in prior years show the core constraint is not direct product cost; it is the inability to spread corporate costs across meaningful revenue.

Liquidity is exceptionally thin: FY2022 ended with just $15.8K of current assets against $33.4M of current liabilities, and total liabilities rose from $17.8M to $33.5M while total assets fell to $1.3M. That leaves the balance sheet shaped by accumulated obligations rather than liquid resources or retained operating cash.

Financial Health Signals

Financial health score pending refresh

We are recalculating Endonovo Therape's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Altman Z-Score Distress

-121.63

Endonovo Therape scores -121.63, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($145K) relative to total liabilities ($33.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/6

Endonovo Therape passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Interest Coverage At Risk

-2.5x

Endonovo Therape earns $-2.5 in operating income for every $1 of interest expense (-$3.3M vs $1.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$135K

YoY+85.2%

10Y CAGR+16.0%

Endonovo Therape generated $135K in revenue in fiscal year 2022. This represents an increase of 85.2% from the prior year.

EBITDA

-$2.6M

YoY-65.9%

Endonovo Therape's EBITDA was -$2.6M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 65.9% from the prior year.

Net Income

N/A

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$98

YoY-99.9%

5Y CAGR-74.5%

10Y CAGR-18.9%

Endonovo Therape held $98 in cash against $7.2M in long-term debt as of fiscal year 2022.

Dividends Per Share

N/A

Shares Outstanding

194M

YoY+169.8%

Endonovo Therape had 194M shares outstanding in fiscal year 2022. This represents an increase of 169.8% from the prior year.

Margins & Returns

Gross Margin

92.6%

YoY+13.1pp

Endonovo Therape's gross margin was 92.6% in fiscal year 2022, indicating the percentage of revenue retained after direct costs. This is up 13.1 percentage points from the prior year.

Operating Margin

-2411.7%

YoY+634.0pp

Endonovo Therape's operating margin was -2411.7% in fiscal year 2022, reflecting core business profitability. This is up 634.0 percentage points from the prior year.

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

ENDV Income Statement

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Revenue	$135K+85.2%	$73K-55.9%	$166K-46.5%	$310K+272.5%	$83K	N/A
Cost of Revenue	$10K-33.3%	$15K-77.1%	$65K-30.0%	$93K+622.2%	$13K	N/A
Gross Profit	$125K+115.7%	$58K-42.1%	$100K-53.7%	$217K+208.2%	$70K	N/A
R&D Expenses	N/A	$0-100.0%	$3K-97.9%	$153K-44.2%	$274K+138.2%	$115K
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	-$3.3M-46.6%	-$2.2M+23.5%	-$2.9M+23.5%	-$3.8M+8.4%	-$4.2M+9.7%	-$4.6M
Interest Expense	-$1.3M-240.4%	$942K-54.8%	$2.1M+12153.4%	$17K+100.3%	-$5.2M+10.2%	-$5.8M
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$3.1M-684.9%	-$396K	N/A	-$6.4M+40.5%	-$10.8M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21
Revenue	$2K-96.6%	$45K-48.4%	$88K-27.9%	$121K+1008.2%	$11K+1586.2%	$650-71.5%	$2K+622.2%	$316
Cost of Revenue	$827	N/A	$4K-17.9%	$5K+20.8%	$4K+951.4%	$383-46.4%	$714-91.9%	$9K
Gross Profit	$693-98.5%	$45K-45.9%	$84K-28.3%	$117K+1581.8%	$7K+2496.6%	$267-83.0%	$2K+118.3%	-$9K
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	-$473K+58.2%	-$1.1M-113.7%	-$529K-9.6%	-$483K+2.8%	-$497K+72.4%	-$1.8M-270.3%	-$486K-30.0%	-$374K
Interest Expense	-$286K+8.6%	-$313K-1.1%	-$309K0.0%	-$309K+8.6%	-$339K-0.3%	-$338K-0.4%	-$336K-120.3%	$1.7M
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$766K-137.1%	$2.1M	N/A	N/A	-$603K+76.1%	-$2.5M-4.7%	-$2.4M-200.7%	$2.4M
EPS (Diluted)	$0.00+100.0%	$-0.01	$0.00	N/A	$0.00+100.0%	$-0.02+33.3%	$-0.03	N/A

ENDV Balance Sheet

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Total Assets	$1.3M-36.2%	$2.0M-23.0%	$2.6M-20.4%	$3.3M-22.8%	$4.2M-8.0%	$4.6M
Current Assets	$16K-83.3%	$95K+105.4%	$46K-26.2%	$63K-83.6%	$382K+244.1%	$111K
Cash & Equivalents	$98-99.9%	$86K+540.4%	$13K-29.0%	$19K-95.0%	$379K+320.5%	$90K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	$944+0.2%	$942-95.9%	$23K+579.9%	$3K	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$33.5M+88.2%	$17.8M+4.7%	$17.0M-28.6%	$23.8M+52.1%	$15.6M+10.4%	$14.2M
Current Liabilities	$33.4M+88.6%	$17.7M+5.2%	$16.8M-28.8%	$23.6M+52.6%	$15.5M+15.4%	$13.4M
Long-Term Debt	$7.2M-1.4%	$7.3M+6.2%	$6.8M-0.6%	$6.9M-15.7%	$8.2M+10.9%	$7.4M
Total Equity	-$32.2M-104.0%	-$15.8M-9.7%	-$14.4M+29.9%	-$20.5M-80.0%	-$11.4M-19.3%	-$9.6M
Retained Earnings	-$75.1M-33.1%	-$56.4M-5.8%	-$53.3M-0.8%	-$52.9M-48.6%	-$35.6M-22.1%	-$29.2M

Metric	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21
Total Assets	$816K-19.6%	$1.0M-15.4%	$1.2M-6.4%	$1.3M-11.7%	$1.5M-9.0%	$1.6M-12.1%	$1.8M-9.6%	$2.0M
Current Assets	$36K-51.3%	$73K-23.5%	$95K+501.5%	$16K-34.3%	$24K+305.1%	$6K-90.8%	$64K-32.1%	$95K
Cash & Equivalents	$0-100.0%	$33K+198.0%	$11K+11065.3%	$98-99.6%	$23K	$0-100.0%	$60K-30.2%	$86K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	$3K	N/A	$944-0.1%	$9450.0%	$945+0.1%	$944
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$23.8M+1.5%	$23.4M-8.4%	$25.6M-23.6%	$33.5M+58.9%	$21.1M+1.5%	$20.8M+4.5%	$19.9M+11.6%	$17.8M
Current Liabilities	$23.7M+2.4%	$23.1M-9.2%	$25.5M-23.6%	$33.4M+59.1%	$21.0M+1.5%	$20.7M+4.6%	$19.8M+11.7%	$17.7M
Long-Term Debt	$7.1M+0.5%	$7.1M+2.2%	$6.9M-3.5%	$7.2M-1.6%	$7.3M-1.9%	$7.4M+0.7%	$7.4M+1.3%	$7.3M
Total Equity	-$23.0M-2.4%	-$22.4M+8.0%	-$24.4M+24.3%	-$32.2M-64.1%	-$19.6M-2.3%	-$19.2M-6.2%	-$18.0M-14.3%	-$15.8M
Retained Earnings	-$66.6M-1.2%	-$65.9M+3.0%	-$67.9M+9.6%	-$75.1M-21.2%	-$62.0M-1.0%	-$61.4M-4.3%	-$58.9M-4.3%	-$56.4M

ENDV Cash Flow Statement

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Operating Cash Flow	-$679K+31.2%	-$987K-33.0%	-$742K+70.8%	-$2.5M+11.7%	-$2.9M+3.7%	-$3.0M
Capital Expenditures	N/A	N/A	N/A	$3K-71.1%	$9K	N/A
Free Cash Flow	N/A	N/A	N/A	-$2.5M+11.9%	-$2.9M	N/A
Investing Cash Flow	N/A	N/A	N/A	-$3K+71.1%	-$9K+99.7%	-$3.0M
Financing Cash Flow	$593K-44.0%	$1.1M+43.9%	$736K-66.3%	$2.2M-31.3%	$3.2M-47.3%	$6.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21
Operating Cash Flow	-$65K+60.6%	-$166K+4.2%	-$173K+23.2%	-$226K-82.1%	-$124K+40.0%	-$206K-67.9%	-$123K+68.6%	-$391K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$33K-82.5%	$188K+1.9%	$184K-9.1%	$203K+37.8%	$147K+0.3%	$147K+51.0%	$97K-79.4%	$472K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ENDV Financial Ratios

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Gross Margin	92.6%+13.1pp	79.5%+18.9pp	60.6%-9.3pp	69.9%-14.6pp	84.5%	N/A
Operating Margin	-2411.7%+634.0pp	-3045.7%-1289.2pp	-1756.5%-528.4pp	-1228.1%+3767.3pp	-4995.3%	N/A
Net Margin	N/A	-4247.2%-4008.6pp	-238.6%	N/A	-7729.5%	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	-154.7%-139.5pp	-15.2%	N/A	-151.7%+82.7pp	-234.4%
Current Ratio	0.000.0	0.010.0	0.000.0	0.00-0.0	0.02+0.0	0.01
Debt-to-Equity	-0.22+0.2	-0.46+0.0	-0.48-0.1	-0.34+0.4	-0.72+0.1	-0.77
FCF Margin	N/A	N/A	N/A	-820.1%+2648.2pp	-3468.3%	N/A

Metric	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21
Gross Margin	45.6%-54.4pp	100.0%+4.6pp	95.4%-0.5pp	96.0%+32.7pp	63.3%+22.2pp	41.1%-27.6pp	68.7%+2772.8pp	-2704.1%
Operating Margin	-31105.1%-28602.2pp	-2502.9%-1898.3pp	-604.6%-206.9pp	-397.7%+4135.0pp	-4532.7%+272198.0pp	-276730.6%-255443.9pp	-21286.7%+97002.6pp	-118289.2%
Net Margin	-50405.9%-54971.5pp	4565.6%	N/A	N/A	-5505.1%+383130.4pp	-388635.5%-282885.8pp	-105749.7%-864082.0pp	758332.3%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-93.9%-297.3pp	203.4%	N/A	N/A	-41.6%+116.8pp	-158.4%-25.4pp	-133.0%-252.3pp	119.4%
Current Ratio	0.000.0	0.000.0	0.000.0	0.000.0	0.000.0	0.000.0	0.000.0	0.01
Debt-to-Equity	-0.310.0	-0.31-0.0	-0.28-0.1	-0.22+0.1	-0.37+0.0	-0.39+0.0	-0.41+0.1	-0.46
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$32.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Globestar Therapeutics Corp GSTC

$124K

Tracon Pharmaceu TCON

$4.3M

Trevena Inc TRVN

$1.3M

Scorpius Holdings SCPX

$1.5M

Vincerx Pharma Inc VINC

$3.5M

Frequently Asked Questions

What is Endonovo Therape's annual revenue?

Endonovo Therape (ENDV) reported $135K in total revenue for fiscal year 2022. This represents a 85.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Endonovo Therape's revenue growing?

Endonovo Therape (ENDV) revenue grew by 85.2% year-over-year, from $73K to $135K in fiscal year 2022.

What is Endonovo Therape's EBITDA?

Endonovo Therape (ENDV) had EBITDA of -$2.6M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Endonovo Therape have?

As of fiscal year 2022, Endonovo Therape (ENDV) had $98 in cash and equivalents against $7.2M in long-term debt.

What is Endonovo Therape's gross margin?

Endonovo Therape (ENDV) had a gross margin of 92.6% in fiscal year 2022, indicating the percentage of revenue retained after direct costs of goods sold.

What is Endonovo Therape's operating margin?

Endonovo Therape (ENDV) had an operating margin of -2411.7% in fiscal year 2022, reflecting the profitability of core business operations before interest and taxes.

What is Endonovo Therape's operating cash flow?

Endonovo Therape (ENDV) generated -$679K in operating cash flow during fiscal year 2022, representing cash generated from core business activities.

What are Endonovo Therape's total assets?

Endonovo Therape (ENDV) had $1.3M in total assets as of fiscal year 2022, including both current and long-term assets.

How many shares does Endonovo Therape have outstanding?

Endonovo Therape (ENDV) had 194M shares outstanding as of fiscal year 2022.

What is Endonovo Therape's current ratio?

Endonovo Therape (ENDV) had a current ratio of 0.00 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.

What is Endonovo Therape's debt-to-equity ratio?

Endonovo Therape (ENDV) had a debt-to-equity ratio of -0.22 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Endonovo Therape's cash runway?

Based on fiscal year 2022 data, Endonovo Therape (ENDV) had $98 in cash against an annual operating cash burn of $679K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Endonovo Therape's debt-to-equity ratio negative or unusual?

Endonovo Therape (ENDV) has negative shareholder equity of -$32.2M as of fiscal year 2022, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Endonovo Therape's Altman Z-Score?

Endonovo Therape (ENDV) has an Altman Z-Score of -121.63, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Endonovo Therape's Piotroski F-Score?

Endonovo Therape (ENDV) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Can Endonovo Therape cover its interest payments?

Endonovo Therape (ENDV) has an interest coverage ratio of -2.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.